CME Information - Division of Hematology

Accreditation Statement

The School of Medicine of the University of North Carolina at Chapel Hill is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Statement

The School of Medicine of the University of North Carolina at Chapel Hill designates this live activity for a maximum of 6.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure statement

This activity has been planned and implemented under the sole supervision of the Co-Course Directors, Jared Weiss, MD, and Kaitlin Morrison, PhD, and the planning committee of Shetal Patel, MD, PhD, and Sid Sheth, DO, MPH, in association with the UNC Office of Continuing Professional Development (UNC CPD).

Dr. Weiss holds stock or stock options in Achilles Therapeutics, Alnylam Pharmaceuticals, En Fuego Therapeutics, Lyell Immunopharma, Merus NV, Nektar Therapeutics, Nuvalent, Vertex Pharmaceuticals, and Vesselon; receives consulting fees from Abbvie, Amgen, AstraZeneca, BeiGene, EMD Serono, G1 Therapeutics, Genentech, Gilead, Jounce, Merck, Nanobiotix, PDS Biotech, and Sanofi; and research support from G1 Therapeutics, Genmab, Immunicum (aka Mendus), Iovance, Loxo/Lilly, Mirati, Nurix, PDS Biotech, TScan Therapeutics, and Verastem.

Dr. Morrison and UNC CPD staff have no financial relationships with ineligible companies as defined by the ACCME.

Dr. Brahmer receives consulting fees from Amgen, AstraZeneca, BMS, Eli Lilly, Genentech/Roche, GlaxoSmithKline, Janssen, Johnson & Johnson, Merck, Regeneron, and Sanofi; research grants from AstraZeneca and BMS, and is on a Data & Safety Monitoring Board for Janssen.

Dr. Liu receives consulting fees from Abbvie, Amgen, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Catalyst, Daiichi Sankyo, Eisai, Elevation Oncology, Genentech/Roche, Gilead, Guardant Health, Janssen, Jazz Pharmaceuticals, Merck, Merus, Mirati, Novartis, Pfizer, Regeneron, Sanofi, Takeda, and Turning Point Therapeutics; research support from Abbvie, Alkermes, Elevation Oncology, Ellipses, Genentech, Gilead, Merck, Merus, Nuvalent, RAPT, and Turning Point Therapeutics; and is on a Data & Safety Monitoring Board for Candel Therapeutics.

Dr. Merker receives consulting fees from Velsera and research support from Illumina.

Dr. Patel receives consulting fees from Beigene; research support from Amgen, Dracen Pharmaceuticals, Genentech/Roche, Guardant Health, LOXO/Lilly, and Seattle Genetics; and is on a Data & Safety Monitoring Board for G1 Therapeutics.

Dr. Shen receives consulting fees from GT Medical Technologies, Johnson & Johnson, and Nanobiotix, and research support from AstraZeneca.

Dr. Sheth receives speaker fees from Exelixis and Medscape, consulting fees from Eisai, Exelixis, and Naveris, and research support from AstraZeneca, Exelixis, Merck, and Regeneron.

Dr. Socinski receives speaker fees from AstraZeneca, G1 Therapeutics, Genentech, Guardant, Lilly, Janssen, Jazz, Mirati, and Regeneron; consulting fees from BeiGene, Genentech, Gilead, Lilly, Mirarti, OncoCyte, and Spectrum; research support from BeiGene, Cullinan, Daiichi Sanyko, Enliven, Genentech, OncocCyte, Spectrum, and Takeda; and is on the steering committee/DSMB for AstraZeneca, Beigene, Bristol Myers Squibb, and Summit.

Dr. Yarbrough has no financial relationships with ineligible companies as defined by the ACCME.

This activity has not received financial support from ineligible companies.